DK3884947T3 - Forøgelse af lægemiddelbiotilgængelighed i naltrexonterapi - Google Patents

Forøgelse af lægemiddelbiotilgængelighed i naltrexonterapi Download PDF

Info

Publication number
DK3884947T3
DK3884947T3 DK21152314.7T DK21152314T DK3884947T3 DK 3884947 T3 DK3884947 T3 DK 3884947T3 DK 21152314 T DK21152314 T DK 21152314T DK 3884947 T3 DK3884947 T3 DK 3884947T3
Authority
DK
Denmark
Prior art keywords
enhancement
drug bioavailability
naltrexone therapy
naltrexone
therapy
Prior art date
Application number
DK21152314.7T
Other languages
Danish (da)
English (en)
Inventor
Shawn Flanagan
Eduardo Dunayevich
Original Assignee
Nalpropion Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46172304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3884947(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nalpropion Pharmaceuticals Llc filed Critical Nalpropion Pharmaceuticals Llc
Application granted granted Critical
Publication of DK3884947T3 publication Critical patent/DK3884947T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M21/00Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Acoustics & Sound (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
DK21152314.7T 2010-12-03 2011-12-02 Forøgelse af lægemiddelbiotilgængelighed i naltrexonterapi DK3884947T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41939510P 2010-12-03 2010-12-03
EP17156985.8A EP3222280B1 (en) 2010-12-03 2011-12-02 Increasing drug bioavailability in naltrexone therapy

Publications (1)

Publication Number Publication Date
DK3884947T3 true DK3884947T3 (da) 2024-01-22

Family

ID=46172304

Family Applications (4)

Application Number Title Priority Date Filing Date
DK21152314.7T DK3884947T3 (da) 2010-12-03 2011-12-02 Forøgelse af lægemiddelbiotilgængelighed i naltrexonterapi
DK11845186.3T DK2646031T3 (en) 2010-12-03 2011-12-02 Increased drug bioavailability in naltrexone therapy
DK23209711.3T DK4349369T3 (da) 2010-12-03 2011-12-02 Forøgelse af biotilgængelighed af lægemiddel i naltrexonbehandling
DK17156985.8T DK3222280T3 (da) 2010-12-03 2011-12-02 Forøgelse af lægemiddelbiotilgængelighed i naltrexonbehandling

Family Applications After (3)

Application Number Title Priority Date Filing Date
DK11845186.3T DK2646031T3 (en) 2010-12-03 2011-12-02 Increased drug bioavailability in naltrexone therapy
DK23209711.3T DK4349369T3 (da) 2010-12-03 2011-12-02 Forøgelse af biotilgængelighed af lægemiddel i naltrexonbehandling
DK17156985.8T DK3222280T3 (da) 2010-12-03 2011-12-02 Forøgelse af lægemiddelbiotilgængelighed i naltrexonbehandling

Country Status (27)

Country Link
US (1) US20130245056A1 (enExample)
EP (4) EP4349369B1 (enExample)
JP (5) JP6008866B2 (enExample)
KR (5) KR20140035320A (enExample)
CN (1) CN103313711A (enExample)
AR (2) AR093182A1 (enExample)
AU (2) AU2011336304B2 (enExample)
BR (1) BR112013013390A2 (enExample)
CA (2) CA2819262C (enExample)
CL (1) CL2013001564A1 (enExample)
CY (2) CY1118968T1 (enExample)
DK (4) DK3884947T3 (enExample)
ES (2) ES2866879T3 (enExample)
FI (2) FI4349369T3 (enExample)
HR (4) HRP20251576T1 (enExample)
HU (3) HUE034393T2 (enExample)
IL (3) IL226504B (enExample)
LT (4) LT3222280T (enExample)
MX (2) MX384662B (enExample)
PL (3) PL3884947T3 (enExample)
PT (4) PT4349369T (enExample)
RS (3) RS65198B1 (enExample)
RU (1) RU2640561C2 (enExample)
SI (3) SI2646031T1 (enExample)
SM (4) SMT201700232T1 (enExample)
TW (1) TWI618536B (enExample)
WO (1) WO2012075459A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1784221B (zh) 2003-04-29 2010-07-07 奥雷西根治疗公司 影响体重减轻的组合物
JP5180092B2 (ja) 2005-11-22 2013-04-10 オレキシジェン・セラピューティクス・インコーポレーテッド インスリン感受性を増すための組成物および方法
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
JP6196041B2 (ja) 2010-01-11 2017-09-13 オレキシジェン・セラピューティクス・インコーポレーテッド 大うつ病を有する患者において減量療法を提供する方法
CA2819262C (en) * 2010-12-03 2024-05-28 Orexigen Therapeutics, Inc. Pharmaceutical composition comprising naltrexone and buopropion for administration with food
FI4104824T3 (fi) 2012-06-06 2025-08-06 Nalpropion Pharmaceuticals Llc Koostumus käytettäväksi ylipainon ja liikalihavuuden hoitomenetelmässä potilailla, joilla on suuri sydän- ja verisuonitaudin riski
US20180015042A1 (en) * 2015-02-07 2018-01-18 Intas Pharmaceuticals Ltd. Pharmaceutical composition for the treatment of obesity
AU2018244806B2 (en) * 2017-03-28 2023-12-21 LDN Pharma Limited An agent that increases the expression of the Bcl2-associated agonist of cell death for the treatment of cancer
EP3482751A1 (en) 2017-11-14 2019-05-15 LDN Pharma Limited Cancer treatment
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10129265A1 (de) * 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
US6972291B2 (en) * 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake
EP1772147A2 (en) * 2003-03-17 2007-04-11 Japan Tobacco, Inc. Method for increasing the oral bioavailability of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate
CN1784221B (zh) 2003-04-29 2010-07-07 奥雷西根治疗公司 影响体重减轻的组合物
US20070117827A1 (en) 2005-07-27 2007-05-24 Gary Tollefson Compositions for affecting weight loss
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
JP5180092B2 (ja) 2005-11-22 2013-04-10 オレキシジェン・セラピューティクス・インコーポレーテッド インスリン感受性を増すための組成物および方法
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US20070179168A1 (en) 2005-11-28 2007-08-02 Orexigen Therapeutics, Inc. Methods of treating anxiety disorders
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
EP2484346B1 (en) 2006-06-19 2017-02-22 Alpharma Pharmaceuticals LLC Pharmaceutical compositions
KR101264789B1 (ko) * 2006-06-30 2013-05-15 엘지디스플레이 주식회사 횡전계 방식 액정표시장치용 어레이 기판과 그 제조방법
WO2008011150A1 (en) 2006-07-20 2008-01-24 Somaxon Pharmaceuticals, Inc. Methods of improving the pharmacokinetics of doxepin
AU2007319471B9 (en) * 2006-11-09 2012-10-04 Nalpropion Pharmaceuticals Llc Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer
US20080110792A1 (en) * 2006-11-09 2008-05-15 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
EP4029519A1 (en) * 2007-04-11 2022-07-20 BioMarin Pharmaceutical Inc. Tetrahydrobiopterin for treating conditions associated with elevated phenylalanine levels
DE102007036076A1 (de) 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
US8318813B2 (en) * 2007-09-13 2012-11-27 Lcs Group, Llc Method of treating binge eating disorder
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
CA2819262C (en) * 2010-12-03 2024-05-28 Orexigen Therapeutics, Inc. Pharmaceutical composition comprising naltrexone and buopropion for administration with food

Also Published As

Publication number Publication date
PL3884947T3 (pl) 2024-05-06
EP3222280A1 (en) 2017-09-27
JP7025319B2 (ja) 2022-02-24
JP2024071605A (ja) 2024-05-24
CY1118968T1 (el) 2018-01-10
EP2646031A1 (en) 2013-10-09
IL270841A (en) 2020-01-30
HRP20170734T1 (hr) 2017-08-11
SI2646031T1 (sl) 2017-07-31
CL2013001564A1 (es) 2014-05-02
KR102105857B1 (ko) 2020-05-04
RU2640561C2 (ru) 2018-01-09
SI3884947T1 (sl) 2024-06-28
JP2016210809A (ja) 2016-12-15
MX384662B (es) 2025-03-14
EP3884947A1 (en) 2021-09-29
EP4349369A3 (en) 2024-05-15
FI3884947T3 (fi) 2024-01-30
HRP20210618T1 (hr) 2021-09-17
US20130245056A1 (en) 2013-09-19
KR20200044158A (ko) 2020-04-28
IL226504B (en) 2021-01-31
EP4349369A2 (en) 2024-04-10
HUE034393T2 (en) 2018-02-28
TW201304780A (zh) 2013-02-01
RU2013127423A (ru) 2015-01-10
AU2011336304B2 (en) 2017-03-30
PT3222280T (pt) 2021-04-22
TWI618536B (zh) 2018-03-21
MX2013006071A (es) 2013-10-01
DK3222280T3 (da) 2021-04-19
KR20190058702A (ko) 2019-05-29
BR112013013390A2 (pt) 2016-09-06
CA2819262A1 (en) 2012-06-07
KR101984500B1 (ko) 2019-05-31
EP3222280B1 (en) 2021-01-20
RS56014B1 (sr) 2017-09-29
EP2646031A4 (en) 2014-04-23
HUE053831T2 (hu) 2021-07-28
JP6456890B2 (ja) 2019-01-23
SI3222280T1 (sl) 2021-11-30
HUE065852T2 (hu) 2024-06-28
JP6008866B2 (ja) 2016-10-19
SMT202400038T1 (it) 2024-03-13
ES2625527T3 (es) 2017-07-19
WO2012075459A1 (en) 2012-06-07
CA2819262C (en) 2024-05-28
SMT201700232T1 (it) 2017-07-18
AR124500A2 (es) 2023-04-05
DK2646031T3 (en) 2017-05-22
AU2011336304A1 (en) 2013-07-11
JP2022060331A (ja) 2022-04-14
PL3222280T3 (pl) 2021-11-29
EP3884947B1 (en) 2023-11-15
HRP20240115T1 (hr) 2024-06-07
ES2866879T3 (es) 2021-10-20
IL279626A (en) 2021-03-01
EP4349369B1 (en) 2025-09-17
EP2646031B1 (en) 2017-02-22
PT4349369T (pt) 2025-12-17
AR093182A1 (es) 2015-05-27
KR20140035320A (ko) 2014-03-21
CA3239386A1 (en) 2012-06-07
LT3884947T (lt) 2024-03-12
RS65198B1 (sr) 2024-03-29
PL2646031T3 (pl) 2017-08-31
PT3884947T (pt) 2024-02-16
KR20210063473A (ko) 2021-06-01
ES2625527T9 (es) 2018-09-25
LT3222280T (lt) 2021-05-10
JP2013544290A (ja) 2013-12-12
LT2646031T (lt) 2017-06-26
DK4349369T3 (da) 2025-12-22
SMT202500474T1 (it) 2026-01-12
KR20180069089A (ko) 2018-06-22
EP2646031B9 (en) 2018-01-10
AU2017204309A1 (en) 2017-07-13
SMT202100227T1 (it) 2021-07-12
CY1124331T1 (el) 2022-07-22
RU2017144631A3 (enExample) 2021-04-13
RU2017144631A (ru) 2019-02-18
RS62149B1 (sr) 2021-08-31
FI4349369T3 (fi) 2025-12-17
MX356801B (es) 2018-06-13
KR102258043B1 (ko) 2021-05-28
KR102391511B1 (ko) 2022-04-26
JP2019056004A (ja) 2019-04-11
CN103313711A (zh) 2013-09-18
HRP20251576T1 (hr) 2026-01-30
LT4349369T (lt) 2026-01-12
PT2646031T (pt) 2017-05-25

Similar Documents

Publication Publication Date Title
CY2018029I2 (el) Αντι-ιικη θεραπεια
DK3884947T3 (da) Forøgelse af lægemiddelbiotilgængelighed i naltrexonterapi
IL245328A0 (en) Pharmaceutical composition
PL2552438T3 (pl) Sposoby leczenia raka wątrobowokomórkowego
HRP20150029T1 (xx) Farmaceutski pripravak za lijeäśenje metaboliäśkog sindroma
CO6910189A2 (es) Derivado heterociclico y farmacéutico
EP2720699A4 (en) ADMINISTRATION OF BENZODIAZEPINE
HUE048876T2 (hu) Rákos megbetegedések kezelése
DK3603704T3 (da) Indgivelse af medikament
PL2739153T3 (pl) Leczenie raka sutka
DK2717941T3 (da) Behandling af cancer
PL2771037T3 (pl) Środki terapeutyczne i ich zastosowania
EP2442821A4 (en) SAFE ADMINISTRATION OF DESMOPRESSIN
HRP20180567T1 (hr) Farmaceutski pripravak omeprazola
CO6880064A2 (es) Métodos terapéuticos
DK2420219T3 (da) Indgivelsesport
EP2687212A4 (en) DRUG
DK2694056T3 (da) Terapeutisk behandling
ES1075603Y (es) Objeto terapeutico